NUTEX HEALTH INC (NUTX) Stock Fundamental Analysis
USA - NASDAQ:NUTX - US67079U3068 - Common Stock
96.11 USD
+3.15 (+3.39%)
95 USD
-1.11 (-1.15%)
We assign a fundamental rating of 6 out of 10 to NUTX. NUTX was compared to 101 industry peers in the Health Care Providers & Services industry. NUTX has only an average score on both its financial health and profitability. NUTX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! With these ratings, NUTX could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
In the past year NUTX was profitable.
In the past year NUTX had a positive cash flow from operations.
In the past 5 years NUTX reported 4 times negative net income.
In multiple years NUTX reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of NUTX (8.82%) is better than 93.07% of its industry peers.
NUTX's Return On Equity of 34.08% is amongst the best of the industry. NUTX outperforms 95.05% of its industry peers.
With an excellent Return On Invested Capital value of 30.54%, NUTX belongs to the best of the industry, outperforming 99.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROIC | 30.54% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NUTX's Profit Margin of 10.76% is amongst the best of the industry. NUTX outperforms 94.06% of its industry peers.
The Operating Margin of NUTX (33.39%) is better than 99.01% of its industry peers.
NUTX has a Gross Margin of 48.77%. This is in the better half of the industry: NUTX outperforms 74.26% of its industry peers.
NUTX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NUTX is creating value.
NUTX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for NUTX has been increased compared to 5 years ago.
NUTX has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.02 indicates that NUTX is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.02, NUTX perfoms like the industry average, outperforming 48.51% of the companies in the same industry.
NUTX has a debt to FCF ratio of 4.45. This is a neutral value as NUTX would need 4.45 years to pay back of all of its debts.
NUTX has a Debt to FCF ratio of 4.45. This is in the better half of the industry: NUTX outperforms 73.27% of its industry peers.
NUTX has a Debt/Equity ratio of 1.46. This is a high value indicating a heavy dependency on external financing.
NUTX has a Debt to Equity ratio of 1.46. This is in the lower half of the industry: NUTX underperforms 68.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Altman-Z | 2.02 |
ROIC/WACC4.1
WACC7.45%
2.3 Liquidity
A Current Ratio of 2.27 indicates that NUTX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.27, NUTX is in the better half of the industry, outperforming 78.22% of the companies in the same industry.
NUTX has a Quick Ratio of 2.26. This indicates that NUTX is financially healthy and has no problem in meeting its short term obligations.
NUTX has a Quick ratio of 2.26. This is in the better half of the industry: NUTX outperforms 78.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 430.28% over the past year.
NUTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 141.25%.
The Revenue has been growing by 222.96% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
3.2 Future
Based on estimates for the next years, NUTX will show a very strong growth in Earnings Per Share. The EPS will grow by 25.68% on average per year.
NUTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 62.77% yearly.
EPS Next Y-9.22%
EPS Next 2Y25.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year157.98%
Revenue Next 2Y62.77%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 8.08, the valuation of NUTX can be described as reasonable.
NUTX's Price/Earnings ratio is rather cheap when compared to the industry. NUTX is cheaper than 95.05% of the companies in the same industry.
NUTX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.38.
A Price/Forward Earnings ratio of 6.97 indicates a rather cheap valuation of NUTX.
97.03% of the companies in the same industry are more expensive than NUTX, based on the Price/Forward Earnings ratio.
NUTX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.08 | ||
| Fwd PE | 6.97 |
4.2 Price Multiples
NUTX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NUTX is cheaper than 99.01% of the companies in the same industry.
90.10% of the companies in the same industry are more expensive than NUTX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.7 | ||
| EV/EBITDA | 3.29 |
4.3 Compensation for Growth
The decent profitability rating of NUTX may justify a higher PE ratio.
A more expensive valuation may be justified as NUTX's earnings are expected to grow with 25.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.68%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for NUTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
96.11
+3.15 (+3.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners21.51%
Inst Owner Change60.68%
Ins Owners3.03%
Ins Owner Change0%
Market Cap534.37M
Analysts82.22
Price Target246.5 (156.48%)
Short Float %31.23%
Short Ratio4.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.25
Dividend Growth(5Y)N/A
DP19.83%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4474.63%
Min EPS beat(2)9.6%
Max EPS beat(2)8939.67%
EPS beat(4)3
Avg EPS beat(4)2105.75%
Min EPS beat(4)-602.61%
Max EPS beat(4)8939.67%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)143.87%
Min Revenue beat(2)76.42%
Max Revenue beat(2)211.33%
Revenue beat(4)4
Avg Revenue beat(4)75.65%
Min Revenue beat(4)5.5%
Max Revenue beat(4)211.33%
Revenue beat(8)5
Avg Revenue beat(8)36.33%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.68%
PT rev (3m)24.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-169.52%
EPS NY rev (1m)0%
EPS NY rev (3m)-26.7%
Revenue NQ rev (1m)9.14%
Revenue NQ rev (3m)3.17%
Revenue NY rev (1m)5.33%
Revenue NY rev (3m)0.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.08 | ||
| Fwd PE | 6.97 | ||
| P/S | 0.86 | ||
| P/FCF | 7.7 | ||
| P/OCF | 7.52 | ||
| P/B | 2.71 | ||
| P/tB | 3.18 | ||
| EV/EBITDA | 3.29 |
EPS(TTM)11.89
EY12.37%
EPS(NY)13.79
Fwd EY14.35%
FCF(TTM)12.49
FCFY12.99%
OCF(TTM)12.78
OCFY13.3%
SpS112.28
BVpS35.45
TBVpS30.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROCE | 35.61% | ||
| ROIC | 30.54% | ||
| ROICexc | 35.64% | ||
| ROICexgc | 37.81% | ||
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% | ||
| FCFM | 11.12% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
F-Score8
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Debt/EBITDA | 1.26 | ||
| Cap/Depr | 8.22% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 59.03 | ||
| Cash Conversion | 31.12% | ||
| Profit Quality | 103.36% | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 2.02 |
F-Score8
WACC7.45%
ROIC/WACC4.1
Cap/Depr(3y)59.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
EPS Next Y-9.22%
EPS Next 2Y25.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
Revenue Next Year157.98%
Revenue Next 2Y62.77%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4652.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1011.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y98.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.51%
OCF growth 3YN/A
OCF growth 5YN/A